1- American Diabetes Association (2007): “Diagnosis and Classification of Diabetes Mellitus”, Diabetes care journal 30: S42 – S47.
2- Le TK, Able SL, Lage MJ (2006). Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression.Cost EffResourAlloc. 4: 18.
3- American Diabetes Association, Inc. (2007): “Diabetes: Magnitude and Mechanisms”, Clinical Diabetes Journal 25: 25 – 28.
4- Shim, M. and England, T. Updated: 5/10/2004. Diabetes mellitus. (cited 2004, may 6), Available from:specialtyLaboratorie.
5- Horseman, N.D. (1996). The physiology of fuel nutrients and pancreatic hormones. In: Essentials of physiology. 2nd edition.Little, Brown and company. Boston P:599-60.
6- Fox, I.S. (2002): Endocrine Glands. In: Human Physiology. 7th ed., McGraw- Hill companies, New York, Chap.11, pp: 299-302.
7- Murray, K.R.; Granner, K. D. and Mayes, A. P., (2000): Pituitary and Hypothalamic Hormones. In: Harper's Biochemistry. 25th ed.., Appleton and Lange, Stamford, Chap.45, pp: 552 – 554.
8- Frazer, A. ;Molinoff, P.B. and Winokur, A. (1994). Biological bases of brain function and disease. Raven press، Ltd، U.S.A. Pp : 47-49.
9- Kandell ER, Schwartz JH, Jessell TM (2000). Principles of Neural Science. 4th ed. New York, USA: McGraw-Hill. pp. 893,896.
10- Cooper JR, Bloom FE, Roth RH (1996). The Biochemical Basis of Neuropharmacology. 7th ed. NewYork, USA: Oxford University Press. pp.352-391.
11-Hardeland R,Pandi-Perumal SR&Cardinali DP, (2006) Melatonin. Int J Biochem Cell Biol, 38, 313-6.
12- Herrera MR, Manjarrez GG, Nishimura ME, Hernandez-RJ (2003). Serotonin-related tryptophan in children with insulin-dependent diabetes. Pediatric Neurol 28:20– 23.
13- Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P (1988). Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest. 18:399–404.
14- Schloss P, Williams DC (1998). The serotonin transporter: a primary target for antidepressant drugs. Biochemistry Department University of Dublin, Trinity College Ireland.J Psychopharmacol. 12.2:115-21.
15- William, F.Ganong, (1999). Review of medical physiology. University of California.Synaptic Transmission pp.92-94.
16- Ragoobirsingh, D & Morrison, E.Y. (1992): “Change in Serum Cholinesterase Activity in Jamaican Diabetes”, Journal of the National Medical Association, VOL. 84, No.10 pp: 853-855.
17- Inacio L.G., Stefanello F, Sausen L.D., Maria M.V., Schetinger M.R. &Goncalves J.F (,2006). “ Serum cholinesterase activity in diabetes and associated pathologies ” Diabetes Res.72(1):28-32.
18- Rose, L.,Davis, D.A.andLehmaan, H., Lancet(1965). pp 225,563.
19- Vandekar, M. (1978). WHO/ VBS/ 78, 692.
20-Harenberg,J,Huhle,G.,Giese Ch., Wang،L., Feuring ،M., Song, X., Hofmann،U.: (2000). Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin induced. thrombocytopenia. british journal of Hematology 109 182-186 Address :Harenbergj.,University of Heidelberg،Germany.
21-American Diabetes Association (2002): “Elevated Serum Concentration of Adipose-Derived Factor, Adiponectin, in Patients With Type 1 Diabetes”, Diabetes care journal V 25: pp 1665-1666.
22- World Health Organization (1999): Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of WHO consultation. Part 1: Diagnosis and classification of diabetes Mellitus. Geneva, World Health Org.
23- Cataline, F. P.; Mallo, F. and Andrade, A. M. (2002): “AHered GH Elimination kinetics in Type 1 Diabetes Mellitus can Explain the Elevation in Circulating Levels: Bicompartmental Approach” J. clin. Endocrinol.Metab., 87 (4): 1785 – 1790.
24- Kareem, I.; Jaweed, S. A. and Bardapurkar, V. P. (2004):“Study of magnesium, Glycosylated hemoglobin and lipid profile in diabetic retinopathy” clin. Biochem., 19 (20): 124 – 127.
25- O’Brien, S.F; Watts, G.G; Powrie, J.K; shaw، K.M; Miller, N.J. (1996). "Lipds lipoproteins antioxidants and glomerulan and tubular dysfunction in type I diabetes". Diabetes. Res. Clin. Pract. 32 (1-2): 81-90.
26- Maechler, P., Wollheim C., Bentzen, C. and Niesors E. (1993). Importance of exogenous cholesterol in diabetic rates: effect of treatment with insulin deficiency or with an Acyl-coA: cholersterol acyl tranceferase-inhibtor. Ann. Nutr. Metab., 37: 199-209.
27-- Maxwell, S; Holm, G; Bondjers, G, Wiklurd, O. (1997). "Comparison of antioxidant in lipoprotein fraction from insulin-dependent diabeties and healthy controls".Atherosclerosis. 129(1): 89-96.
28- Rubins, H.B., Robins, S.J., Collins, D. (2002). Treating Diabetic Dyslipidemia with Gemfibrozil for secondary prevention of coronary Heart Diseaes. Veterans Affairs High-Density Cholesterol Intervention trial study Group. N EnglJ.Med. 341:410-8.
29- Bishop M., Duben – Engel Kirk J.andfody E.(2000) Clinical chemistry 4th ed., Lippincot Williams and Wilkins, Philadelphia, USA., PP. 220 – 221.
30- Magarian EO, Dietz AJ (1 987). Correlation of cholinesterase with serum lipids and lipoproteins.J ClinPharmacol. 27:819-820
31- Osada J, Aykegas H, Cao G, Micro-obradors J, Palacious- Alaiz E (1989). Changes in serum cholinesterase (EC 3.11.88) activity in rats consuming a high-fat diet. Br J Nutr.62:343-348.
32- Cucuianu M, Opincaru A, Tapalaga D (1978). Similar behaviour of lecithin-cholesterol acyltransferase and pseudocholinesterasein liver disease and hyperlipoproteinemia.ClinChimActa85 : 73–79.
33- Malyszko J, Urano T, Knofler R, et al (1994) Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res. 75:569–76.
34- Eriksson E. & Humble M. (1990) Serotonin in psychiatric pathophysiology. A review of data from experimental and clinical research., Basel, Karger.
35- Berry WTC, Cowin PJ, Davies DR (1954). A relationship between body fat and plasma pseudo-cholinesterase.Br J Nutr. 8: 79–82.
36- Al-Mutawaa A M J M (2010),The role of calcium ion cholinesterase activity and its correlation with some metal ions in sera with type II Diabetes mellitus،thesis phd،university of basrah.
37- Jafri SM, Chandra N, Dhawan S, Soni D, Chandra M, Shanker K (1992). Factors influencing platelet serotonin uptake in essential hypertension. Int J Cardiol.;34:327–333.
38- Heron D, Sminitzky M, Hershkowitz M (1980). Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. ProcNatlAcadSci USA.77:7463-7.
)
